CNS Pharmaceuticals Inc.

2.06-0.0200-0.96%Vol 49.92K1Y Perf -33.33%
Apr 19th, 2021 10:53 DELAYED
BID2.04 ASK2.07
Open2.10 Previous Close2.08
Pre-Market- After-Market-
 - -%  - -
Target Price
8.33 
Analyst Rating
Strong Buy 1.00
Potential %
306.34 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap52.12M 
Earnings Rating
Price Range Ratio 52W %
16.38 
Earnings Date
21st May 2021

Today's Price Range

2.032.12

52W Range

1.594.46

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.73%
1 Month
-26.50%
3 Months
8.33%
6 Months
13.66%
1 Year
-33.33%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CNSP2.06-0.0200-0.96
AAPL134.720.56000.42
GOOG2 300.652.89000.13
MSFT259.85-0.8900-0.34
XOM56.12-0.5400-0.95
WFC44.000.16000.36
JNJ162.660.42000.26
FB304.10-2.0800-0.68
GE13.29-0.1000-0.75
JPM152.30-1.0000-0.65
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.09-0.18-100.00
Q02 2020--0.15-
Q01 2020--0.12-
Q04 2019--0.17-
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date21st May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume49.92K
Shares Outstanding25.30M
Trades Count343
Dollar Volume915.30K
Avg. Volume1.49M
Avg. Weekly Volume173.46K
Avg. Monthly Volume189.45K
Avg. Quarterly Volume1.51M

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) stock closed at 2.08 per share at the end of the most recent trading day (a 2.46% change compared to the prior day closing price) with a volume of 339.33K shares and market capitalization of 52.12M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. CNS Pharmaceuticals Inc. CEO is John M Climaco.

The one-year performance of CNS Pharmaceuticals Inc. stock is -33.33%, while year-to-date (YTD) performance is 16.85%. CNSP stock has a five-year performance of %. Its 52-week range is between 1.59 and 4.46, which gives CNSP stock a 52-week price range ratio of 16.38%

CNS Pharmaceuticals Inc. currently has a PE ratio of -4.00, a price-to-book (PB) ratio of 4.14, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -454.83%, a ROC of -1 091.57% and a ROE of -1 977.19%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CNS Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. CNS Pharmaceuticals Inc.’s next earnings report date is 21st May 2021.

The consensus rating of Wall Street analysts for CNS Pharmaceuticals Inc. is Strong Buy (1), with a target price of $8.33, which is +306.34% compared to the current price. The earnings rating for CNS Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CNS Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CNS Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.30, ATR14 : 0.27, CCI20 : -121.39, Chaikin Money Flow : -0.31, MACD : -0.18, Money Flow Index : 26.74, ROC : -10.34, RSI : 43.58, STOCH (14,3) : 22.64, STOCH RSI : 0.69, UO : 36.29, Williams %R : -77.36), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CNS Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma.

CEO: John M Climaco

Telephone: +1 800 946-9185

Address: 2100 West Loop South, Houston 77027, TX, US

Number of employees: 3

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

News

Stocktwits